Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

STOK Stoke Therapeutics Inc

10,48

-0,14 (-1,32%)

Última atualização: 16:33:19

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

12/09/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

12/15/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Jonathan Allan

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Stoke Therapeutics (NASDAQ:STOK)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Click aqui para mais gráficos Stoke Therapeutics.

Stoke Therapeutics (NASDAQ:STOK)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025

Click aqui para mais gráficos Stoke Therapeutics.

Notícias Stoke Therapeutics Inc

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Quarta, 8 de Janeiro de 2025 (3 semanas atrás) • Business Wire

Form 8-K - Current report
Terça, 7 de Janeiro de 2025 (3 semanas atrás) • Edgar (US Regulatory)

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
Terça, 7 de Janeiro de 2025 (3 semanas atrás) • Business Wire

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
Segunda, 6 de Janeiro de 2025 (3 semanas atrás) • Business Wire

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Sexta, 27 de Dezembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 27 de Dezembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Segunda, 23 de Dezembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 11 de Dezembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 11 de Dezembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Terça, 10 de Dezembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Terça, 10 de Dezembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Segunda, 9 de Dezembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Mais Notícias de Stoke Therapeutics Inc

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições